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ABSTRACT 
 
Melanoma is one of the most studied neoplasia, although laboratory techniques used for 
investigating this tumor are not fully reliable. Animal models may not predict the human 
response due to differences in skin physiology and immunity. In addition, international 
guidelines recommend to develop processes that contribute to the reduction, refinement and 
replacement of animals for experiments (3Rs). Adherent cell culture has been widely used for 
the study of melanoma to obtain important information regarding melanoma biology. 
Nonetheless, these cells grow in adhesion on the culture substrate which differs considerably 
from the situation in vivo. Melanoma grows in a 3D spatial conformation where cells are 
subjected to a heterogeneous exposure to oxygen and nutrient. In addition, cell-cell and cell-
matrix interaction play a crucial role in the pathobiology of the tumor as well as in the 
response to therapeutic agents. To better study melanoma new techniques, including spherical 
models, tumorospheres, and melanoma skin equivalents have been developed. These 3D 
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models allow to study tumors in a microenvironment that is more close to the in vivo situation, 
and are less expensive and time consuming than animal studies. This review will also describe 
the new technologies applied to skin reconstructs such as organ-on-a-chip that allows skin 
perfusion through microfluidic platforms. Although 3D in vitro models still need to be 
implemented, we expect to achieve a model morphologically, based on the new technologies, 
are becoming dynamically similar to normal and diseased skinmore sophisticated, representing 
at a great extent the in the near future, withvivo situation, the “perfect” model that will allow 
less involvement of animals up to their complete replacement, is still far from being achieved. 
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Melanoma, 3D models, spheroids, skin equivalents, skin-on-a-chip  
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1. INTRODUCTION 
Malignant melanoma (MM) is a highly aggressive cancer of the skin originating from 
melanocytes. MM is the most life-threatening tumor of the skin (70%), although melanomait 
represents only 4% of all skin cancers [1]. MM is regarded as a major health problem due to the 
high mortality associated with tumor and to its growing incidence. According to the World 
Health Organization, 132,000 melanoma skin cancers occur globally each year. The metastatic 
stage represents the major therapeutic challenge, as responders to conventional chemotherapy 
are still below 20% for mono- and below 30% for poly-chemotherapy [2]. 
Melanoma is a heterogeneous disease, which suggests a richly complex etiology. Deep 
molecular analyses have revealed consistent genetic patterns among different melanoma 
subtypes. The latest estimate of mutation burdens is of ∼17 mutations per Mb calculated by 
TCGA from whole-exome sequencing (WES) of 318 primary and metastatic melanomas 
originating from non-glabrous (hair-bearing) skin [3]. In melanoma, it was possible to isolate 
single cells of BRAF V600E/wt-NRASand wt-BRAF/NRASQ16R genotypes from the same lesion 
[4]. In other studies, melanomas express heterogeneously tumor-associated antigens such as 
gp100 and melanoma antigen recognized by T cells-1 (MART-1) [5]. Cells not expressing MART-
1 and gp100 escape immune surveillance, which may explain past failures in passive and active 
immunotherapies [6]. Future efforts will need to focus on targeting multiple coexistent 
aberrations in different pathways and addressing the mechanisms that underlie the tumor’s 
propensity for growth and chemoresistance [7]. This in turn will lead to a rational basis for 
combinations of targeted treatments aimed at circumventing mechanisms of resistance to yield 
a clinical benefit. To these purposes, there is an evident need of tools that allow a better 
understanding of the pathomechanisms involved in melanoma. Moreover, it will be of 
paramount importance to develop new tools to evaluate the efficacy of novel therapeutic 
strategies. 
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5
   Currently, different animal models are used to study melanoma development and to asses 
efficacy and safety of drugs in preclinical phase. Human tumor xenografts of established 
human melanoma cell lines or primary melanoma cells implanted subcutaneously and 
intradermally into immunosuppressed mice, allow the study of primary tumors and metastases 
[8]. Metastatic melanoma cell lines or primary tumor cells, also injected into the mice tail vein [9], 
spontaneously metastasize to distant sites, such as the lung. Alternatively, tumor cells are 
injected into the mice tail vein [9].injected into the mice tail vein [9], spontaneously metastasize. 
However, established cell lines become inexorably altered in the process, thereby limiting their 
ability to predict clinical outcome and drug activity. Recently, the use of primary melanoma 
cells rather than established melanoma cell lines has become a standard for xenografting [8]. 
The subcutaneous transplants of fresh tumor tissue into immunocompromised mice, the 
patient derived xenograft (- PDX) models [10] generates avatars of a melanoma patient who has 
relapsed on a drug. This way, ‘mini human-in-mouse trials’ or ‘co-clinical trials’ can be 
conducted for the selection of effective drugs and dosing regimen for that specific patient [8,10]. 
Recently, using the the melanoma patient-derived orthotopic xenografts (PDOX) model to 
identify efficaceous approved agents and experimental drugs, resected melanoma tissues were 
transplanted into the chest wall of nude mice to mimic the site from which they were taken 
from the patient [11]. However, as with all model systems, the PDXs have limitations, most 
notably the required use of immunocompromised mice. For simulating the natural progression 
of melanoma as it occurs in humans, mouse models that involve the induction of 
carcinogenesis through multistage UVR or chemical agent treatments are also extensively used 
[10,1112,13]. More recently, genetically engineered mouse models have been exploited to study the 
effect of genetic alterations in melanoma initiation, progression, and metastasis [1214]. Moreover, 
with the advancement of next-generation sequencing technology new mutations are being 
identified and new engineered models will be developed. Given that cancer is the product of 
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6
complex interactions between the genotype and environment, the combined use of chemical 
carcinogen and genetically engineered models (GEM) is a logical approach to unravel the 
complex interplay between genetic susceptibility and environmental exposure. The clearest 
example of this is the increased spectrum of tumors observed in some GEM following exposure 
to carcinogens or radiation [11].13]. Less popular rodent models in melanoma research, i.e., Syrian 
golden hamsters and Mongolian gerbils are used for spontaneously occurring melanoma and 
for chemically-induced melanoma respectively [15]. In particular, Syrian hamster, the Bomirski 
melanomas, consists of 5 transplantable in vivo-variants and represent a good animal model 
for developing and testing potential melanoma vaccines [16]. In addition, an important feature 
of the Syrian hamsters is the variability in hair-coat coloration phenotypes, with numerous 
color mutants, which makes them particularly interesting objects of genetic studies and studies 
on the influence of hair color phenotypes on melanoma development [17].  Zebrafish model 
represents an alternative xenotransplant model in vivo that offers a rapid, efficient approach 
for assessing drug effects on human cancer cells at various stages of tumorigenesis [1318]. 
Zebrafish embryos are particularly useful for microscopic analysis as they are translucent, thus 
offering the opportunity to visualize the metastatic process at high resolution [1419]. 
   However, in most instances, animal models may not predict the human response due to 
differences in skin physiology and immunity [15,1620,21]. International guidelines on the use of 
animals for regulatory purposes are also increasingly making recommendations to develop 
processes that contribute to the reduction, refinement and replacement of animals for 
experiments (3Rs) [1722].  Many industries now highlight the 3Rs as part of their corporate social 
responsibility, while the academic science base new exciting technologies, including stem cell, 
3-dimensional (3D) tissue constructs, bioprinting and organ-on-chips are being developed. 
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7
The availability of such systems and the easy access to melanoma cells have leaded to the 
development of various 2D and 3D melanoma models in vitro, whereby many questions will 
likely be addressed, without the use of animals. 
 
2. MELANOMA CELL CULTURES 
In vitro adherent cell culture of human melanoma cells includes their isolation and growing as 
a monolayer on plastic or coated tissue plates. Most studies on melanoma cell biology and 
preliminary screening of toxicity and efficacy of potential therapeutic molecules are performed 
in monolayer cultures [18,1923,24]. Although these methodologies are easy to perform and have 
been instrumental for advancing our understanding of tumor biology, in 2D cultures, cancer 
cells organize as a monolayer, as opposed to the 3D more physiological structure. Malignant 
transformation, primarily driven by genetic mutations in cells, is also accompanied by specific 
changes in cellular and extra-cellular mechanical properties, such as stiffness and adhesion [20]. 
Mechanobiological25]. While new computational approaches have detected similarity between 
tumor and cell lines [26], mechanobiological signaling in 2D culture systems still fail to mimic 
solid tumors. In particular, the mechanical regulation influencing tumor growth in vivo and 
some characteristics, such as for instance hypoxia inside the tumor mass, cannot be 
reproduced in 2D cultures. Monolayer cultures do not recapitulate many of the complex 
properties of the in vivo melanoma microenvironment. In particular, cell cultures cannot 
reproduce melanoma cell interactions with extracellular matrix (ECM) and cell–to-cell 
communications required to regulate polarity, proliferation, adhesion, survival and proteolytic 
cleavage of the microenvironment, responsible for tumor metastasis. Indeed, the composition 
and 3D structure of the ECM undergo a continuous remodeling during tumor progression [2127]. 
In addition, different drug responses were observed for cells grown in 3D cultures, as 
compared with 2D monolayers [2228]. Finally, cells cultured in 3D models are more resistant than 
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8
2D cultures to anticancer drugs [23,2429,30]. For these reasons, the evolution of the 3D culture 
systems can bridge the gap between traditional 2D cultures and in vivo melanoma models. 
 
 
3. MELANOMA 3D MODELS 
Over the last ten years, numerous 3D melanoma models have been developed. Spheroids can 
be formed only by cancer cells (monoculture) or by combining cancer and stromal cells (co-
colture). The so called tumorosphere, is being increasingly used as an in vitro assay to study 
melanoma cancer stem cells (CSC). Skin equivalent is an advanced 3D model, which allows to 
study melanocyte/keratinocyte interaction in an in vitro reconstitute epidermis. In the last few 
year, microfluidic culture devices or skin on a chip models have become available, and 
reproduce a dynamic skin reconstruct, more similar to the in vivo situation. 
The 3D culture models represent a breakthrough in cancer research and development of new 
anti-cancer therapeutic strategies, fulfilling the principle of the 3Rs with the final reduction of 
animal experiments. 
 
3.1 SPHERICAL MODELS 
The multicellular tumor spheroid (MCTS) was first developed by Sutherland and co-workers in 
the early 70s [2531]. MTCS are composed by tumor cells grown in particular conditions allowing 
the formation of sphere-like 3D structure.  
It is well known that spheroid models better simulate the growth and microenvironment 
conditions of the tumor in vivo.  In particular, MTCS show critical physiologic parameters, 
including cell-cell adhesion, barriers to mass transport, extracellular matrix deposition, cell-
matrix adhesion and, in some cases, a necrotic core surrounded by a viable layer of quiescent 
and/or proliferating cells [26,2732,33]. Comparative studies have shown that numerous genes 
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9
associated with cell survival, proliferation, differentiation and resistance to therapy are 
differentially expressed in cells grown as MCTS versus 2D cultures [28,29,3034,35,36].  
We previously demonstrated that in melanoma MCTS the expression level of several melanoma 
markers (CD271, HIF-1α, ABCB5 and Oct4) observed in skin lesion and freshly isolated cells are 
maintained in spheroids derived from the same patients up to 168h [3137]. 
Over the years, several approaches have been proposed for MCTS generation. They are divided 
in scaffold-free and scaffold-based systems (Fig. 1). In the scaffold–free system, formation of 
MTCS occurs when tumor cells are placed in an environment where cell–cell interactions 
dominate over cell–substrate interactions and spontaneously aggregate to form a spherical 3D 
structure [3238]. This non-adherent condition can be recreated by several techniques. The most 
used approach is the liquid overlay method where tumor cells are seeded on culture plate 
previously coated with a thin layer of inert substrate, such as agar, agarose or polyHEMA [3339]. 
The liquid overlay method leads to reproducible formation of one single MCTS per well, 
homogenous in size which makes them ideal for high-throughput screening of new therapeutic 
agents [3440]. We have validated the spheroid model by using melanoma cell lines (primary 
radial growth phase or vertical growth phase and metastasis) (Fig. 2). Melanoma cells cultured 
in 2D showed fail to show differences among cell lines. On the other hand, when cells are 
cultured as MCTS, well distinct morphologic features appear already at 24 hours (Fig. 2A). In 
addition, MCTS are able to reflect the in vivo behavior, as shown by the growth curve and pixel 
areas typical of their original tumor cell (Fig. 2B and 2C).  
The “hanging drop” cell culture is an alternative method to generate MTCS. In this case, a drop 
of cells suspension is placed on the lid of an inverted petri dish, thus letting cells grow in 
suspension avoiding the plate surface (Fig. 1). This technique is useful to amplify cells in a 3D 
system, but it is necessary to transfer MTCS in another plate for further investigation.   
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10
Spheroids can also be generated by a bioreactor (spinner flask or microgravity) or by a 
rotatory cell culture system, where cells are driven to self-aggregate under dynamic culture 
condition. These methods allow the production of a large quantities of MCTS but not uniform 
in size [35,3641,42] (Fig.1). Recently, the formation of MCTS by encapsulating tumor cells in a Ca-
aliginate based membranes (Fig. 1) was described. This approach allows the preparation of 
large quantities of MCTSs of a well-defined size, but seems to reduce oxygen, nutrients and 
contact between cells [37,3843,44].  However, an aqueous core enclosed by hydrogel shell without 
water-immiscible condition was recently developed to overcome this limitation [3945]. 
MCTS can also be formed by using a synthetic cyclic RGD (Arg-Gly-Asp) peptide, called cyclo-
RGDfK(TPP). The RDG-motif, present in several ECM proteins is responsible for binding to 
integrins, thus providing cell to cell and cell-to-matrix interaction [4046]. Akasov and co-workers 
were able to induce the cell self-assembly of both normal and tumor cells by adding the cyclic 
RGDfK and the cyclo-RGDfK(TTP) directly to the monolayer cultures obtaining spheroids that 
were homogenous in size and useful to evaluate the cytotoxic effect of antitumor drugs [4147]. 
The scaffold-based method consists in the use of a porous 3D scaffold which physically 
supports cell aggregation, allowing the formation of MCTS with a controlled size. Several 
scaffolds have been developed [42,4348,49], in particular, Gong et al. created an agarose-based 
scaffold consisting in a micropore scaffold adaptable to 6-24-well plates. This system allows 
the rapid cellular assembly of cells to MCTS and It is completely transparent, allowing to 
monitor the spheroids formation by optical microscope [4450]. 
   Several studies have demonstrated that spheroids more accurately mimic the drug 
sensitivity/resistence of cancer cells of the real tumor. For this reason, spheroids are widely 
used as a model for drug screening and development [45,3451,40]. Both melanoma cell lines and 
human primary and metastatic cells could be employed to form MCTS and used to test new 
anti-tumor drugs in a contest that better reflect the in vivo behaviour of the tumor than 2D 
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11
monolayer condition. In order to predict the efficacy of new therapies, several tests could be 
performed directly on MCTS, including MTT assay, the measure of spheroids area in pixel, the 
apoptotic assay and the live-died assay based on Calcein AM and PI staining. Since MCTS 
resemble the tumor in vivo, they are a good model for study the tumor pathobiology in vitro. 
All molecular methods can be applied to study cells from spheroids at the cellular, protein, 
RNA and DNA level. The use of MCTS have increased the understanding of the intricate cell-
cell and cell-matrix interaction [4652], hypoxia [4753]  and tumor metabolism [4854]. MCTS are also 
reliable in the study tumor progression and invasion, as well as in the evaluation of drugs 
effects on cells migration. They overcome the limitation of the most used invasion assay, such 
as the cell culture wound closure assay and the transwell cell migration and invasion assay, 
which are not able to recapitulate the 3D invasion that occurs in vivo [4955].  Different matrices 
are used to recapitulate the natural tumor microenvironment and evaluate cell migration 
[50,51,5256,57,58]. The so called “collagen invasion assay”, in which spheroids are immersed in a type 
I collagen matrix, is the most used method to assess the invasive capacity of cells in MCTS.  
Figure 3 shows an example of this assay performed by using five melanoma cell lines of 
different origin. To quantify the invasive ability, it is possible to measure the spheroids area 
and the invasion area in pixel by ImageJ software, the factor shape, the percentage of 
fragmentation and the distance reached by cells, as reported in several studies [53,49,3159,55,37]. It 
should be also noted that the presence of stromal cells would better recapitulate the tumor 
microenvironment. These cells release growth factors and ECM components that influence 
tumor cell growth and migratory ability. Immune cells, fibroblast and endothelial cells are 
frequently used in tumor cells co-cultures. They could be seeded both after the formation of 
cancer MCTS or together with tumor cells in non-adherent conditions. The formation of MCTS 
with endothelial cells for the study of angiogenesis is widely recognised [54,5560,61]. In addition, 
Marrero and co-workers reported an innovative spheroid model made by HaCaT cells grown 
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12
by using the bioreactor system known as the High Aspect Ratio Vessel (HARVs) in a 
microgravity environment. The HaCaT cells formed spheroids which were used as a scaffold to 
support the growth of B16.F10 mouse melanoma cells [5662]. 
 
3.2 TUMOROSPHERE 
MCTS is an innovative 3D model useful to study tumor cells in a contest that better mimic the 
tumor microenvironment, but it does not allow to isolate and expand specific tumor cell sub-
population. Cancer stem cells (CSC) are a small cell sub-population within a tumor equipped 
with self-renewal capacity and responsible for tumor maintenance and growth [57,58,5963,64,65]. A 
system to expand mammalian stem cells in a sphere-like in vitro model was first described by 
Singh and co-workers who isolated and characterized normal neural stem cells grown as free-
floating spheres, called neurospheres [6066]. In the last years, this spherical model was applied to 
the CSC isolation from wide range of solid tumors, including melanoma [61,62,63,64,3867,68,69,70,44]. 
The sphere formation assay consists in culturing cells at low-density in a specific medium in 
low-adherent conditions, where single cell is able to give rise to non-adherent sphere by clonal 
expansion [65,6071,66]. A number of CSC markers, including CD133 [6672], the ABC transporter (ATP-
binding cassette) involved in drug efflux (ABCB5) [6773], CD20 [6874], CD24 [6975], CD271 [7076] are 
preliminary used to sort and to enrich the population. Nevertheless, this assay presents several 
disadvantages and limitations, such as excessive sensitivity to the culture method used (i.e. 
media composition, volume, surface area, etc.). In addition, cell density could favor cell fusion 
and aggregation rather than clonal expansion, while more differentiated cells exhibit sphere-
forming capacity. Thus, the standard technique to evaluate the presence of CSC remain the 
transplantation of few cells into immunocompromised mouse and the observation of the 
capacity of continuously forming tumors after several xenotransplant experiment. The in vitro 
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13
3D methods remain a surrogate CSC assay which allow to reliably obtain an enrichment of 
tumor sub-population of CSC [77,78]. 
 
3.3 HUMAN SKIN EQUIVALENTS 
As mentioned before, the interactions between tumor cell, neighbouring normal cell and ECM 
are extremely important as they are responsible for the control of cell behaviour and tissue 
homeostasis [7179]. Studies indicate that basic fibroblast growth factor (bFGF) appear to be 
important in the promotion of melanoma proliferation and invasion [7280]. Cancer-associated 
fibroblasts (CAFs) are an activated sub-population of stromal fibroblasts that have acquired a 
modified phenotype. CAFs have a prominent role in cancer development from initiation, to 
primary and metastatic progression and in drug resistance [73,7481,82]. Recently, Dror and 
colleagues demonstrated that melanoma cells communicate with fibroblasts via melanosomes 
at the early steps of development, resulting in CAF formation [7583]. Although MCTS recapitulate 
the 3D structure of the tumor, they fail to reproduce the complex organization of the tissue in 
vivo. In fact, they do not comprise the epidermal and dermal component that may influence 
melanoma invasiveness and aggressiveness.  
   Human skin equivalent (HSE) is an advanced 3D models which consists of in vitro 
reconstructed skin from isolated primary human cutaneous cells (keratinocytes, melanocytes 
and fibroblast) and ECM components. After the formation of each compartments, the 
reconstructed skin is left at the air-liquid interface allowing keratinocyte differentiation and 
stratification [7684]. Histologically, HSE architecture and composition closely resemble human 
skin [7785,8,7886].  HSE has been used as an alternative to animal testing for studies of skin barrier 
function, skin irritation, wound healing, ultraviolet light-induced damage, for the treatment of 
burns and other wounds [79,80,8187,88,89]. Moreover, this 3D model can be effectively used to study 
cell-cell interactions and effects of the stromal environment in the regulation of melanogenesis, 
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[81,90], proliferation and differentiation of keratinocytes. Furthermore, they can easily be 
engineered with specific genetic alterations in either dermal or epidermal compartments.  
   Also tumor cells, including melanoma, could be incorporate into HSE, thus providing an 
excellent model to study the progression and invasion of the tumor, as well as an excellent 
system for pharmacological analyses, reducing time and cost usually associated to animal 
experiments [7785]. Several approaches have been described to generate melanoma skin 
equivalent (MSE) in vitro. These protocols were firstly developed to generate healthy HSE, and 
melanoma cells were seeded with keratinocytes on the reconstructed dermis (Fig. 4A). One 
approach consists in the use of human de-epidermized dermis (DED). Skin biopsy of a donor is 
deprived of the epidermal layer by overnight incubation in sodium chloride and digested with 
Dispase II to remove the basement membrane. DED is placed on a sterile stainless steel rings 
with a diameter of 6 mm in a 24 well tissue plate. Primary keratinocytes, fibroblasts and 
melanoma cells are seeded together on DED and grown submerged for 24 hours, followed by 
5-20 days of culture at the air-liquid interface to allow keratinocyte differentiation and 
stratification [82,7891,86]. 
In the collagen-based approach, dermis is reconstructed starting by acellular solution, 
consisting of rat tail or bovine type I collagen, which are placed on a tissue culture insert. After 
its polymerization, a cellular solution, consisting of human fibroblast and collagen I, is seeded 
on it and left in submerged condition for 5 days allowing the contraction of the collagen. 
Subsequently, primary human keratinocytes and melanoma cells are seeded onto the dermis 
and left in submerged condition for 4-5 days and at air-liquid interface for 5 to 20 days [7280]. 
Other authors have developed an organotypic skin-melanoma spheroids model where 
melanoma MCTS are incorporated in the dermal compartment instead of being seeded 
together with keratinocytes above the collagen-derived dermal equivalents. In this model, 
MCTS in the dermis closely resemble the in vivo cutaneous melanoma metastases, resulting in 
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15
a large dermal melanoma nest instead that unpredictable nests that results by the approaches 
described above [2]. Recently, a new fully humanized MSE have been developed by Hill and co-
workers, by using an inert porous scaffold (Alvetex®, Reinnrvate Ltd, Reprocell group) 
incorporated with human fibroblasts to generate the dermis. This system overcomes the use of 
collagen derived from bovine or rat tail which are not representative of the normal skin 
microenvironment. The scaffold allows the 3D growth of fibroblasts, which are stimulated to 
produce their own ECM constituents, forming a stable human-like dermal compartment. In 
addition, in this method, melanoma cells are seeded onto the dermal equivalent prior the 
incorporation of keratinocytes, placing them in their original microenvironment [8392]. 
It has been established that melanoma cells in HSE show a striking similarity to the growth and 
invasion properties of the lesion from which they are taken. MM progression consists of two 
phases, the Radial Growth Phase (RGP), where melanoma cells proliferate horizontally in the 
epidermis, and of a Vertical Growth Phase (VGP), where the tumor is more aggressive, and cells 
proliferate vertically invading the dermis [93]. As shown in figure 4B, primary RGP cell lines 
(WM115), stained with S100, are localized in the epidermis, while SkMel28 cell lines, derived 
from a more aggressive primary tumor with vertical growth, are localized at the dermal-
epidermal junction. For this reason, MSE are widely used as an invaluable tool for the 
investigation of melanoma progression and spreading [83,7292,80]. which could help to understand 
the intricate process that leads to switch from radial to vertical growth and the invasion into 
the underlying tissue. In particular, melanoma invasion can be easily quantified by measuring 
the distance in depth reached by cells in the dermis [7886]. Finally, it is possible to test the anti-
migratory effect of different drugs.  
MSE is an attractive preclinical testing tools for novel therapeutic approaches, which could be 
useful to test efficacy as well as the pharmaceutical penetration and absorption by topical or 
intravenous administration of different drug. Since MSE is composed by different cell 
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16
populations consisting of normal and tumor cells, it is also possible to test the toxicities of the 
drug by evaluating the effect on the surrounding non-transformed cells [84,8594,95]. 
However, the environment of melanoma in patients is even more complex, comprising of more 
cell types, such as immune cells, endothelial cells and adipocytes. Some authors have 
developed full thickness HSE, including the hypodermal components and Langerhans cells 
forming a tri-layered structure which mimics the full spectrum of biological functions of the 
real skin [86,8796,97].  A more complex MSE could allow to study the impact of soluble factors or 
cytokines released from tumor cells or surrounding cells on melanoma invasion, drug response 
in a context that is more closed to in vivo.  
Additive manufacturing allows creating a complex tissue layer by layer in a process called 
“bioprinting” in which living cells, ECM components and biomaterials together with growth 
factors are 3D- printed in an intermingled fashion mimicking nature [8898]. The interest in 
bioprinting has significantly grown within the scientific and medical communities due to several 
key advantages over conventional 3D culture methods [8999]. These include the capacity to 
create realistic, geometrically-complex morphologies formed by viable cells, high throughput, 
precise reproducibility, low cost and a limited need for specialized training. However, a 
complete 3D bioprinted human skin featuring all cell types has not yet been developed. The 
lack of vascular and lymphoid systems represents the principal drawback.  
 
 
3.4 MELANOMA-ON-CHIPS  
Various organ-on-chip models are under development to reconstruct in vitro complex 
microenvironments and to overcome some of the organotypic culture limitations, such as 
inefficient tissue perfusion. Microfluidic platform are devices where living cells can be cultured 
and continuously infused in micrometer-sized chambers, allowing a controlled release of 
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17
growth factors or nutrients [90100]. Integration of microfluidics and electrical sensing modality in 
3D tumour microenvironment may provide a powerful platform to accurately and rapidly 
monitor the response of cancer cells to a series of drugs [91101]. In addition, the on-a-chip 
approach at small-scale makes this platform also considerably cost-effective for drug screening 
applications [92102]. Mori and co-workers in a perfusable skin equivalent model with vascular 
channels coated with endothelial cells were able to measure the cell density and distribution 
following perfusion and the amount of drug absorbed into the vascular channel [93103]. Abaci 
and co-workers using a skin-on-a-chip platform with a unique capability to recirculate the 
medium, demonstrated that the cancer drug, doxorubicin, may have direct toxic effects on 
keratinocyte proliferation and differentiation [94104]. Pandya and co-workers using a microfluidic 
platform with multiple chambers and perfusion channels were able to delineate the drug 
susceptible and tolerant/resistant cancer cells in less than 12 hours [95105]. In addition, the 
implementation of nanotechnology-based microfluidics has given the possibility to explore cell 
interactions on a microscale level such as those occurring within a tumour immune-
environment [96106]. A simple microfluidic structure (cell-on-chip), where both melanoma and 
immune cells could mutually migrate through the whole system, revealed that the mutual 
interactions between splenocytes and melanoma cells were markedly different depending on 
the nature of the spleen cells. In details, splenocytes appeared to possess markedly different 
migratory abilities when co-loaded with melanoma cells. On the other hand, melanoma cells 
displayed greater propensity to invade the microchannels in the presence of interferon 
regulatory factor 8 (IRF-8) KO splenocytes rather than when co-cultured with WT cells [96106]. 
Although it is necessary to develop and validate further platforms with reproducible tissue 
function levels, the ongoing models demonstrate a great potential to study healthy and 
diseased skin. Future improvements in biomaterials and microfluidic approaches are expected 
to obtain a reproducibility and efficiency of complex human tumour skin models including 
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18
various skin components and patient-specific cells. The optimization of microenvironment will 
facilitate the comprehension of the mechanisms underlying melanoma development and 
progression and, in addition to the integration of biomarkers/biosensors, the on-a-chip 
approach will revolutionize the drug screening and development, determining a more precise 
basis for providing personalized medicine.  
 
4. CONCLUSIONS 
Although 3D in vitro models are more and more efficient and sophisticated, they cannot fully 
replace the use of animals. They still need to be implemented to achieve a model that 
represents the in vivo situation in all its components morphologically and dynamically. 
GivenDespite the ongoing progresses in technologies applied to 3D reconstructs, we expect to 
have the “perfect” model in a very near future, withthat will allow less and less involvement of 
animals up to their complete replacement, is still far from being achieved. 
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FIGURE LEGENDS 
 
Figure 1. Schematic representation of the several approaches to generate multicellular 
tumor spheroids  
 
Figure 2. Evaluation of proliferative capacity of five melanoma cell lines comparing 2D and 
3D models. Five melanoma cell lines of different origin were analyzed: WM115 and WM266-4, 
derived respectively from primary radial growth phase (RGP) and metastatic tumor from the 
same patient; SKMEL28, primary vertical growth phase (VGP) tumor; WM793B and 1205Lu, 
primary RGP and metastatic tumor derived from the same patient. (A) Cells were cultured as 
2D cultures (upper) or by using the liquid overlay method (lower) and pictures of 3D spheroids 
were taken at different time points. (B) The proliferative capacity of cells cultured in 2D and in 
3D was evaluated by MTT assay. (C, D) Pixel analysis of the pictures was performed to calculate 
total area occupied by MCTS. Statistical analysis was performed using the Student’s t-test. * 
p<0.05; ** 0.01<p<0.05 
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Figure 3. Collagen invasion assay. (A) Cells were seeded on agar to form spheroids and, after 
72h of culture, were transferred in a well coated with a solution of collagen I derived from rat 
tail. (B) MCTS in collagen I were followed up and photographed from 24 to 72 hours after 
implanting. (C) To calculate the factor shape and the percentage of fragmentation were used, 
respectively, the following formulas: (perimeter)*2/4π*(area) and (invasion area/ total area) 
*100. (D-E) To quantify the invasive ability the spheroids area (D) and the invasion area (E) 
were measured by ImageJ software. (F) The average distance reached by invasive cells was 
analyzed by ImageJ software making four measurements of the distance from the edge of the 
MCTS in the four cardinal directions. Statistical analysis was performed using the Student’s t-
test. * p<0.05; ** 0.01<p<0.05 
  
Figure 4. Melanoma skin equivalent. (A) Schematic representation of the different approaches 
used to reconstruct MSE. (B) MSE obtained using WM115 (RGP) and SKMEL28 (VGP) cell lines, 
were paraffin-embedded after 6 days of emersion. Sections were stained with S100 antibody 
and DAB was used as cromogen. Scale bar = 100µm. 
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Figure 1. Schematic representation of the several approaches to generate multicellular tumor spheroids  
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Figure 2. Evaluation of proliferative capacity of five melanoma cell lines comparing 2D and 3D models. Five 
melanoma cell lines of different origin were analyzed: WM115 and WM266-4, derived respectively from 
primary radial growth phase (RGP) and metastatic tumor from the same patient; SKMEL28, primary vertical 
growth phase (VGP) tumor; WM793B and 1205Lu, primary RGP and metastatic tumor derived from the 
same patient. (A) Cells were cultured as 2D cultures (upper) or by using the liquid overlay method (lower) 
and pictures of 3D spheroids were taken at different time points. (B) The proliferative capacity of cells 
cultured in 2D and in 3D was evaluated by MTT assay. (C, D) Pixel analysis of the pictures was performed to 
calculate total area occupied by MCTS. Statistical analysis was performed using the Student's t-test. * 
p<0.05; ** 0.01<p<0.05  
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Figure 3. Collagen invasion assay. (A) Cells were seeded on agar to form spheroids and, after 72h of culture, 
were transferred in a well coated with a solution of collagen I derived from rat tail. (B) MCTS in collagen I 
were followed up and photographed from 24 to 72 hours after implanting. (C) To calculate the factor shape 
and the percentage of fragmentation were used, respectively, the following formulas: 
(perimeter)*2/4π*(area) and (invasion area/ total area) *100. (D-E) To quantify the invasive ability the 
spheroids area (D) and the invasion area (E) were measured by ImageJ software. (F) The average distance 
reached by invasive cells was analyzed by ImageJ software making four measurements of the distance from 
the edge of the MCTS in the four cardinal directions. Statistical analysis was performed using the Student's 
t-test. * p<0.05; ** 0.01<p<0.05  
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Figure 4. Melanoma skin equivalent. (A) Schematic representation of the different approaches used to 
reconstruct MSE. (B) MSE obtained using WM115 (RGP) and SKMEL28 (VGP) cell lines, were paraffin-
embedded after 6 days of emersion. Sections were stained with S100 antibody and DAB was used as 
cromogen. Scale bar = 100 m.  
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